Skip to main content

Table 2 Hazards ratio estimate and confidence intervals from proportional hazards modeling of progression to CRPC

From: Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer

  

Univariate analysis

Multivariate analysis

  

Hazard ratio

95% C.I.

P value

Hazard ratio

95% C.I.

P value

Age

 

0.993

0.975-1.011

0.425

0.990

0.972-1.007

0.248

T

T1

1

     
 

T2

1.359

0.315-5.867

0.681

   
 

T3

2.142

0.528-8.691

0.286

   
 

T4

3.336

0.816-13.647

0.094

   

Gleason score

6-8

1

  

1

  
 

9-10

1.518

1.148-2.009

0.003

1.362

1.023-1.813

0.034

PSA at diagnosis

<100

1

  

1

  
 

100-500

1.374

0.981-1.923

0.064

0.990

0.691-1.417

0.955

 

≥500

1.616

1.149-2.271

0.006

1.099

0.682-1.492

0.965

Nadir PSA level

<0.2

1

  

1

  
 

0.2-4

2.778

2.011-3.836

<0.001

2.794

1.984-3.936

<0.001

 

≥4

6.339

4.315-9.313

<0.001

6.332

4.066-9.861

<0.001

Time from PADT to nadir

≥12

1

  

1

  
 

6-12

2.091

1.480-2.953

<0.001

2.245

1.559-3.232

<0.001

 

<6

4.131

2.956-5.774

<0.001

4.408

3.099-6.271

<0.001

  1. 95% CI.: 95% confidence interval.
  2. PADT: primary androgen deprivation therapy.
  3. CRPC: castration resistant prostate cancer.
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us